Safety Tolerability and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  • STATUS
    Recruiting
  • days left to enroll
    58
  • participants needed
    130
  • sponsor
    Ra Pharmaceuticals
Updated on 22 September 2021
corticosteroids
immunosuppressive agents
acetylcholine
serologic test
ra101495
generalized myasthenia gravis

Summary

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

Details
Condition Myasthenia Gravis, Myasthenia Gravis generalised, Myasthenia Gravis (Chronic Weakness)
Treatment Placebo, zilucoplan (RA101495)
Clinical Study IdentifierNCT04115293
SponsorRa Pharmaceuticals
Last Modified on22 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note